SlideShare a Scribd company logo
1 of 16
Download to read offline
1
Thesis & Recommendation Summary
Key Investment Driver #2
Key Investment Driver #3
Catalent is the global leader in the Drug Development
and manufacturing industry. Their client position allows
the company to gain significantly from the sector growth
Unparalleled Business Strategy leading to increased
demand and contracts from leading life sciences
companies, resulting in long-term stable and growing
revenues
As the global industry leader, Catalent maintains this
status through innovation. They have developed
proprietary solutions and hold around 1,300 patents,
allowing them to gain in their industry through size and
revenue
DATE: MM/DD/YY
NYSE: CTLT
Sector: Life Sciences
Industry: Drug Development & Manu.
Associate: Leon Stempert
BU Finance & Investment Club
The industry is growing substantially and Catalent is positioned to
make gains from this growth and continue to lead in its industry.
Headwind: Pricing pressure on Life Sciences companies could slow
the expected growth of the industry
Key Statistics
Market Cap $ 3,627.36
52-Week Range $ 18.92 – 34.40
Enterprise Value $ 5,348.8
Revenue (LTM) $ 669.3
EBITDA $ 450.8
Beta (against RTY) 0.72
Margins & Ratios
P/E (LTM) 1.14x
D/E Ratio 0.52
ROE 155.74%
EBITDA Margin 22.88%
Profit Margin 11.60%
Dividend Yield 0.00%
Recommendation
Current Trading Price: $29.13
(As of x/xx/20xx)
Recommendation: BUY
Target Price: $35.99
Upside/Downside (%) 23.6%
-20.00%
-10.00%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
8/18/14 2/18/15 8/18/15 2/18/16
CTLT vs. RUT vs. PSCH
CTLT Russell 2000 ETF (PSCH)
Key Investment Driver #1
2
INDUSTRY TRENDS & PRIMARY RESEARCH
INDUSTRY OVERVIEW
DATE: MM/DD/YY
Development and Manufacturing: Biosimilar Drug, Etc.
This industry group consists of companies that either discovers,
develop, or manufacture chemically based therapeutic and
preventive medicine, and medicinal products. Companies
included in this industry tend to collaborate with other
pharmaceutical companies
Industry Definition
BU Finance & Investment Club
Overview: Growth in Life Sciences companies are driven by a healthy economy, growing GDP and Global
Healthcare Spending. Factors: Aging Population, Rising Consumer Wealth (Emerging Countries), Proliferation
in chronic diseases (Longer life expectancies, etc.)
Growth: Most sub-industries are expected to grow by 6-10% each year through 2020, and Increased
Acquisitions in the entire sector
Industry Characteristics: High R&D Costs, high capital intense, High Entry Barrier, Medium Competition (On
Focused Researches)
Industry Summary
Growth by Segment:
Pharma Segment sales have slowed in certain global
markets, but are expected to maintain 6-8% to 2020
Biotech sales are expected CAGR of 9.02% through
2020
Generics and biosimilars Segment is expected to grow at
a CAGR of 10.03% through 2017
All other Life Sciences sub-industries are expected to
grow within 6-10%
Growth Drivers: Increased trend towards Universal
healthcare policies (Global Trend), Aging Population
Impact on Company: Catalent end consumers are top
pharmaceutical, Biotech, Generics, biosimilars, and
Medtech companies. Which each segment in high
growth stage, Catalent stands to gain and grow in the
long-term
Trend #1: Optimistic Sector Growth
1831
1587
1398
2408
402
Revenue of Peer Group ($mm)
Catalent ICON Charles River PAREXEL AMRI
$0.00
$1,000.00
$2,000.00
$3,000.00
$4,000.00
2016 2017 2018 2019 2020
Expected High Growth Revenues
3
INDUSTRY TRENDS & PRIMARY RESEARCH
DATE: MM/DD/YYBU Finance & Investment Club
Outlook: M&A has been increasing in this sector over the years. Deal value in 2014 was $351 billion, a 113
percent growth rate from 2013. The first half of 2015 saw 304 pharma deals valued at $221 billion, compared
$62 billion same period 2014.
Key Drivers: Pricing Pressure; strengthening existing product portfolios; replenishing pipelines depleted by
patent expiry; deepening capabilities in priority areas, entering and/or emerging markets, and acquiring
innovative technologies to leverage current assets or generate cost-saving synergies
Impact on Company: Catalent has a unique business model that focuses on development, delivery, and
supply. This makes the company look like a promising acquisition target. This activity also indirectly affects the
company positively through stronger customers that are growing.
Trend #3 Changing Demographics & Policy
Changing Factors: Aging Population, Growing
Prevalence of Chronic Diseases, Rising consumer
wealth, and Universal healthcare programs
Outcome: These factors are expected to boost
healthcare spending and demand for life sciences
products in 2016+
Impact on Company: Catalent supplies drug
products to pharma's and ultimately the consumers.
This changing environment will positively affect the
sales of its services through increased healthcare
spending/demand.
Trend #2: M&A and Collaborations
0
200
400
600
800
1000
1200
(inthousands)
Aging Population (Census Report)
0
10000
20000
30000
40000
50000
60000
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
(Inthousands)
Noncommunicable Diseases (NCD)
4
COMPANY OVERVIEW
DATE: MM/DD/YYBU Finance & Investment Club
Catalent offers a range of life sciences services. From drug and biologic development services to delivery
technologies to supply solutions. With over 80 years of experience, Catalent has the deepest expertise, the
broadest offerings, and the most innovative technologies to help Life Sciences companies get more molecules to
market faster, enhance product performance, and provide superior, reliable manufacturing results.
Business Overview
Drug Development & Formulation Services: With our
broad range of expert services, we drive faster, more
efficient development timelines and produce better
products (Biologics Cell Line, Formulation, Solid State
Services, Etc.)
Drug Delivery Technologies: Offers better treatments and
more value for patients, payers, and innovators with our
innovative delivery technologies and dose forms. (Versatile
SOFTGEL Solutions, Controlled Release, Inhalation,
Injectable, and Oral Fast Dissolve)
Supply Services: Offers global, reliable supply from our
world-class manufacturing and supply network and
integrated solutions
Core Products & Services
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and
medical device industries.
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides
essential products and services to help pharmaceutical and biotechnology companies, government agencies
and academic institutions around the globe to accelerate their research and drug development efforts
PAREXEL International Corp. is a biopharmaceutical services company. It provides clinical research, medical
communications, consulting, commercialization and informatics, and technology services to pharmaceutical,
biotechnology, and medical device industries
Albany Molecular Research, Inc. engages in research and manufacturing organization providing customers
drug discovery, development, and manufacturing services.
Competitors & Competitive Positioning
274.00
314.00
354.00
388.00 413.00 432.00 443.00
2009 2010 2011 2012 2013 2014 2015
Adjusted EBITDA
5
COMPANY OVERVIEW
DATE: MM/DD/YYBU Finance & Investment Club
Catalent generates its revenues through three main segments. Development and Clinical Solutions, Medication
Deliveries Solutions, and Oral Technologies.
Revenue Generation
Finished Product/Service Back to
Company
Drug Manufacturing
Supplies
Pharmaceutical
Raw Material
Supplies
Performed by
Industry Firms
Outsourced
$$$
Drug
Development
& Formulation
Services
Drug Delivery
Technologies
Supply &
Supply
Management
Services
Biotech Companies
Pharmaceutical &
Biopharmaceutical
companies
Generics &
Biosimilar
Companies
$0.00
$250.00
$500.00
$750.00
$1,000.00
$1,250.00
2012 2013 2014 2015
Historical Segment Revenue
Development and Clinical Solutions Medication Deliveries Solutions
Oral Technologies & Others
$0.00
$400.00
$800.00
$1,200.00
$1,600.00
$2,000.00
$2,400.00
$2,800.00
2011 2012 2013 2014 2015
Total Revenue
6
MANAGEMENT OVERVIEW
DATE: MM/DD/YYBU Finance & Investment Club
Management Profiles
John Chiminski -- Holdings: 363,000 shares – No recent activity
Matthew Walsh – Holdings 88,000 shares – No recent activity
Management Ownership & Insider Trading
John Chiminski, CEO
• More than 30+ Years of Experience in the Industry
• Hired as CEO of Catalent in 2009
• Former CEO of GE Medical Diagnostics from 2007-2009, but with GE for over 20 years
• Masters Degree from Kellogg School of Management; BS and MS in Electrical Engineering
at Purdue University
Matthew Walsh, CFO
• Over 8+ Years of Life Sciences Sector experience
• Hired as CFO of Catalent in 2008
• Former CFO of Escala Group, Inc. (Global Collectibles Network and Precious Metals
Trader)
• MBA from Cornell University; BS in Chemical Engineering at Cornell University
Steve Leonard, SVP - Global Operations
• More than 30+ Years of Experience in the Industry
• Promoted to SVP – Global Operations of Catalent in June of 2009
• Former GM of Global Operations at GE Healthcare’s Medical Diagnostics Business
• BS in Mechanical Engineering at Drexel University
Holding Summary
Institutional Holdings 77.5%
Total number of holders 260
Total shares held 97,605,000
Total value of holdings $2,388,394,350
7
MANAGEMENT OVERVIEW
DATE: MM/DD/YYBU Finance & Investment Club
Exhibit X: Insider Trades Summary
COMPANY TRENDS: INVESTMENT THESES
Thesis: Catalent’s client position exposes it to the
future significant growth expected in the life
sciences sector. As more companies look to cut
cost due to pricing pressure by government and
R&D, this will drive growth of Catalent’s financials
Aggressive investments to expand their sales and
marketing activities has led them to grow their
client accounts.
Client Breakdown:
• 82 of top 100 Branded drug marketers
• 19 of top 20 generic marketers
• 40 of top 50 biologics marketers
• 23 of top 25 consumer health marketers
globally
• Key Customers: Pfizer, J&J, GlaxoSmithKline,
Novartis, Roche, Actavis, and Teva
Investment Thesis #1: Global Leader in Drug Development
0
5
10
15
20
3 Months 6 Months
Number of Shares Bought Number of Shares Sold
-0.02%
0.00%
0.02%
0.04%
0.06%
0.08%
0.10%
0.12%
John (CEO) Matthew (CFO) Khichi Samrat Morel Donald E. JR
Insider Share Change
% Change
233.2
268.3
404.8
412.2
438.8
2011 2012 2013 2014 2015
Drug Development Revenues
8
DATE: MM/DD/YYBU Finance & Investment Club
Investment Thesis #2: Unparalleled Business Model
Investment Thesis #3: Patented Proprietary Solutions
Thesis: Catalent business strategy has gained significant demand leading to increased contracts and contract
revenue.
Catalent has an unrivalled and unique Business Strategy by providing advanced delivery technologies and
development solutions, as well as, supply solutions. These three major solutions allow Catalent to capitalize on
demand from businesses looking to market their products faster and grow their business, while reducing the
cost.
Thesis: Catalent continues to innovate and develop proprietary solutions to sustain a competitive advantage in
the industry.
Currently, they have over 1,300 patents in advanced drug delivery and biologics formulations and technologies,
manufacturing, nutritional and pharmaceutical dosage forms, mammalian cell engineering, sterile
manufacturing services, and others.
Notable Patents: Vegicaps and Optishell capsules, and GPEx Technology
COMPANY TRENDS: INVESTMENT THESES
175.3
268.3
404.8
412.2
438.8
2011 2012 2013 2014 2015
Contract Generated Revenue
19.00%
20.00%
21.00%
22.00%
23.00%
24.00%
25.00%
2011 2012 2013 2014 2015
0.0
100.0
200.0
300.0
400.0
500.0
EBITDA & EBITDA Margins
9
GROWTH OPPORTUNITIES & PROJECTIONS
DATE: MM/DD/YYBU Finance & Investment Club
Revenue Summary & Forecast
Growth as per a proxy for revenue
Revenue is expected to grow with the sector through increased healthcare spending, pricing pressure, and
demand from Pharmaceutical, Biotech, Biosimilar, Generics, Consumers, etc.
175
268
405
412 439 467 499 533
570
610
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Drug Development Revenue
224 219 246 262 279
297
317
339
363
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Medication Deliveries Revenue
1,203
1,176 1,169
1,130
1,107
1,096 1,096 1,107
1,118
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Oral Technologies Revenue
1,532
1,695 1,800
1,828 1,831 1,853 1,892 1,947 2,017 2,092
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Total Revenues
10
VALUATION: DISCOUNTED CASH FLOW ANALYSIS
DATE: MM/DD/YYBU Finance & Investment Club
Catalent is a leader in its industry. The industry is expected to grow by ~ 6-10% and Catalent is in the position
to see revenues grow as a result.
Assumptions
WACC Calculation
Risk-Free Rate 1.83%
Equity Risk Premium 6.70%
Size Premium 0.94%
Beta 0.72
Cost of Equity 7.62%
Cost of Debt 2.27%
WACC 5.62%
Historical Forecasted
2012 2013 2014 2015 2016 2017 2018 2019 2020
Revenue Growth 10.6% 6.2% 1.5% 0.2% 1.2% 2.1% 2.9% 3.6% 3.7%
COGS (% of Revenue) 59.42% 59.39% 59.96% 59.43% 58.70% 58.70% 58.70% 58.70% 58.70% 58.70%
EBITDA Growth 2.07% 11.76% 6.97% 2.98% -1.33% 2.08% 2.89% 3.62% 3.71%
EBITDA (% of Revenue) 21.8% 20.10% 21.10% 22.30% 22.90% 22.3% 22.3% 22.3% 22.3% 22.3%
EBIT Growth -1.54% 8.31% 15.70% 5.38% -7.06% 0.86% 1.64% 2.35% 2.42%
EBIT (% of Revenue) 14.0% 12.40% 12.70% 14.40% 15.20% 13.90% 13.80% 13.60% 13.40% 13.30%
NWC 372.2 126.4 162.4 160.1 187.2 204.1 208.4 214.4 222.2 230.4
FCFF Calculation
Forecasted
2016 2017 2018 2019 2020
EBIT $258.38 $260.60 $264.87 $271.09 $277.64
- Taxes $90.43 $91.21 $92.70 $94.88 $97.17
$348.81 $351.81 $357.57 $365.97 $374.81
+ D&A $154.85 $161.24 $169.15 $178.64 $188.76
- CAPEX $196.39 $199.48 $216.46 $235.47 $249.30
- Δ in NWC $16.94 $4.25 $6.01 $7.76 $8.23
Unlevered FCF $290.33 $309.32 $304.24 $301.38 $306.03
Net Present Value $1,285.34
11
VALUATION: DISCOUNTED CASH FLOW ANALYSIS
DATE: MM/DD/YYBU Finance & Investment Club
Terminal Value Calculation
Catalent is about to release its latest fiscal year data in the coming weeks. The data used to calculate the
intrinsic value is a bit stale, however, using the relative value multiple, a more accurate implied price
becomes apparent.
Key Takeaways
DCF Valuation
Growth Rate 2.00%
Undiscounted TEV $ 8,620
Discounted TEV $ 6,558
Implied Exit Multiple 10.20x
Enterprise Value $ 7,843
Equity Value $ 6,122
Implied Share Price $ 49.17
WACC/Growth Rate Price Sensitivity
WACC
$49.17 4% 4.6% 5.1% 5.6% 6.1% 6.6% 7.1% 7.6%
GrowthRate
3.0% $181.03 $121.09 $ 89.47 $ 69.97 $ 56.76 $ 47.23 $ 40.05 $ 34.44
2.5% $123.49 $ 91.26 $ 71.37 $ 57.90 $ 48.19 $ 40.86 $ 35.15 $ 30.57
2.0% $ 93.08 $ 72.80 $ 59.07 $ 49.17 $ 41.70 $ 35.87 $ 31.20 $ 27.39
1.50% $ 74.27 $ 60.27 $ 50.17 $ 42.55 $ 36.61 $ 31.85 $ 27.96 $ 24.73
1.00% $ 61.49 $ 51.19 $ 43.42 $ 37.36 $ 32.51 $ 28.55 $ 25.25 $ 22.47
0.50% $ 52.24 $ 44.32 $ 38.14 $ 33.19 $ 29.15 $ 25.78 $ 22.95 $ 20.52
3.5% $283.42 $178.90 $127.52 $96.96 $76.70 $62.29 $51.51
Valuation Output:
1yr Price Target $ 35.99
Current Price $ 29.13
Upside Potential 23.6%
Recommendation BUY
12
VALUATION: COMPARABLE
COMPANIES ANALYSIS
DATE: MM/DD/YYBU Finance & Investment Club
- Comps Comparable, but not identical. Some comps
have different segments
- More accurate representation of the implied share
price than intrinsic approach
Key Takeaways Name TKR
ICON ICLR
Charles River Labs CRL
PAREXEL PRXL
Albany Molecular Research AMRI
Wide Comparable Companies
Wide CompCo Results
EV/Sales EV/EBITDA
Target 8.0x 11.9x
Max 8.0x 11.9x
Mean 6.1x 10.2x
Median 5.7x 10.0x
Min 4.6x 9.1x
13
DATE: MM/DD/YYBU Finance & Investment Club
VALUATION SUMMARY & RANGE
ANALYSIS
Catalent looks to be positioned to take advantage
of growth in the industry. My price target seems
fairly reasonable. Consider investing into a
company and industry the fund doesn’t have much
exposure to.
Key Takeaways
Methodology Price / Share Weight
Discounted Cash Flow
Perpetuity Growth $16.53 50%
Exit Multiple $25.56 25%
Comparable Company
EV/Sales - Core $16.73 5%
EV/EBITDA $22.35 10%
P/E $19.49 10%
Target Price/Share $35.99
Valuation Summary
>>Income Approach (75%)
• The overall growth expected for the industry is
driving the intrinsic valuation assumptions
>>Market Approach (25%)
• EV/EBITDA more of an appropriate metic for
this industry
• Comps are good comparables, but have other
segments
Assumptions: change weights to fit your
analysis
Valuation Football Field
14
Appendix 1: Income Statement
15
Appendix 2: Balance Sheet
16
Appendix 3: Cash Flow Statement

More Related Content

What's hot

Final_Medtronic+plc+ppt
Final_Medtronic+plc+pptFinal_Medtronic+plc+ppt
Final_Medtronic+plc+pptWill Pan
 
mHealth Israel_Becton Dickinson_US Healthcare Digital Transformation_July 2015
mHealth Israel_Becton Dickinson_US Healthcare Digital Transformation_July 2015mHealth Israel_Becton Dickinson_US Healthcare Digital Transformation_July 2015
mHealth Israel_Becton Dickinson_US Healthcare Digital Transformation_July 2015Levi Shapiro
 
Opportunity analysis of life science tools market in India - A srinivas sash...
Opportunity analysis of life science tools market in India - A  srinivas sash...Opportunity analysis of life science tools market in India - A  srinivas sash...
Opportunity analysis of life science tools market in India - A srinivas sash...Srinivas Sashidhar
 
Dendreon Presentation
Dendreon PresentationDendreon Presentation
Dendreon Presentationafa4
 
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021Mercer Capital
 
Diagnostics Industry Outllook Asia 2009
Diagnostics Industry Outllook Asia 2009Diagnostics Industry Outllook Asia 2009
Diagnostics Industry Outllook Asia 2009Siddharth Singh
 
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...Mercer Capital
 
HIDA Thought Leaders Paper Rodney Rotton
HIDA Thought Leaders Paper Rodney RottonHIDA Thought Leaders Paper Rodney Rotton
HIDA Thought Leaders Paper Rodney RottonRodney Cotton
 
becton dickinson 2008AR
becton dickinson 2008ARbecton dickinson 2008AR
becton dickinson 2008ARfinance45
 
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...Tony Freeman
 
Medical devices equipped for the future
Medical devices equipped for the futureMedical devices equipped for the future
Medical devices equipped for the futureBrand Acumen
 
mHealth Israel_Becton Dickinson_Innovation Strategy_Al Lauritano_Noel Harvey
mHealth Israel_Becton Dickinson_Innovation Strategy_Al Lauritano_Noel HarveymHealth Israel_Becton Dickinson_Innovation Strategy_Al Lauritano_Noel Harvey
mHealth Israel_Becton Dickinson_Innovation Strategy_Al Lauritano_Noel HarveyLevi Shapiro
 
2016 trends in global medical device strategy and issues for the supply chain
2016 trends in global medical device strategy and issues for the supply chain2016 trends in global medical device strategy and issues for the supply chain
2016 trends in global medical device strategy and issues for the supply chainTony Freeman
 

What's hot (19)

Medtronic case ppt
Medtronic case pptMedtronic case ppt
Medtronic case ppt
 
Becton-Dickinson
Becton-DickinsonBecton-Dickinson
Becton-Dickinson
 
Final_Medtronic+plc+ppt
Final_Medtronic+plc+pptFinal_Medtronic+plc+ppt
Final_Medtronic+plc+ppt
 
Life Sciences Trends 2014
Life Sciences Trends 2014Life Sciences Trends 2014
Life Sciences Trends 2014
 
mHealth Israel_Becton Dickinson_US Healthcare Digital Transformation_July 2015
mHealth Israel_Becton Dickinson_US Healthcare Digital Transformation_July 2015mHealth Israel_Becton Dickinson_US Healthcare Digital Transformation_July 2015
mHealth Israel_Becton Dickinson_US Healthcare Digital Transformation_July 2015
 
Opportunity analysis of life science tools market in India - A srinivas sash...
Opportunity analysis of life science tools market in India - A  srinivas sash...Opportunity analysis of life science tools market in India - A  srinivas sash...
Opportunity analysis of life science tools market in India - A srinivas sash...
 
Dendreon Presentation
Dendreon PresentationDendreon Presentation
Dendreon Presentation
 
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021
Mercer Capital's Value Focus: Medical Technology | Mid-Year 2021
 
Diagnostics Industry Outllook Asia 2009
Diagnostics Industry Outllook Asia 2009Diagnostics Industry Outllook Asia 2009
Diagnostics Industry Outllook Asia 2009
 
Top 10 IVD Companies
Top 10 IVD CompaniesTop 10 IVD Companies
Top 10 IVD Companies
 
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
Mercer Capital's Value Focus: Medical Device Manufacturers | Q4 2015 | Five T...
 
HIDA Thought Leaders Paper Rodney Rotton
HIDA Thought Leaders Paper Rodney RottonHIDA Thought Leaders Paper Rodney Rotton
HIDA Thought Leaders Paper Rodney Rotton
 
becton dickinson 2008AR
becton dickinson 2008ARbecton dickinson 2008AR
becton dickinson 2008AR
 
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...
Global Trends in Medical Device and Diagnostic OEM Strategy and Implications ...
 
Medtronic
MedtronicMedtronic
Medtronic
 
Medical devices equipped for the future
Medical devices equipped for the futureMedical devices equipped for the future
Medical devices equipped for the future
 
mHealth Israel_Becton Dickinson_Innovation Strategy_Al Lauritano_Noel Harvey
mHealth Israel_Becton Dickinson_Innovation Strategy_Al Lauritano_Noel HarveymHealth Israel_Becton Dickinson_Innovation Strategy_Al Lauritano_Noel Harvey
mHealth Israel_Becton Dickinson_Innovation Strategy_Al Lauritano_Noel Harvey
 
2016 trends in global medical device strategy and issues for the supply chain
2016 trends in global medical device strategy and issues for the supply chain2016 trends in global medical device strategy and issues for the supply chain
2016 trends in global medical device strategy and issues for the supply chain
 
Rodney POC
Rodney POCRodney POC
Rodney POC
 

Viewers also liked

How to develop_smart_forms_01
How to develop_smart_forms_01How to develop_smart_forms_01
How to develop_smart_forms_01Rafael Rocha
 
Je lance ma startup à l'international avec les nouvelles aides de l'AWEX
Je lance ma startup à l'international avec les nouvelles aides de l'AWEXJe lance ma startup à l'international avec les nouvelles aides de l'AWEX
Je lance ma startup à l'international avec les nouvelles aides de l'AWEXLisa Lombardi
 
Café Numérique Charleroi - Les Femmes dans le Digital 26102016
Café Numérique Charleroi - Les Femmes dans le Digital 26102016 Café Numérique Charleroi - Les Femmes dans le Digital 26102016
Café Numérique Charleroi - Les Femmes dans le Digital 26102016 Lisa Lombardi
 
教学演示技能
教学演示技能教学演示技能
教学演示技能Yee WanWei
 
Online SAP BO 4.2 Training
Online SAP BO 4.2 TrainingOnline SAP BO 4.2 Training
Online SAP BO 4.2 Trainingashok training
 
Go Global! Philippe Rangoni Startups.be
Go Global! Philippe Rangoni Startups.beGo Global! Philippe Rangoni Startups.be
Go Global! Philippe Rangoni Startups.beLisa Lombardi
 
How to Install and Configure your own Identity Manager GE
How to Install and Configure your own Identity Manager GEHow to Install and Configure your own Identity Manager GE
How to Install and Configure your own Identity Manager GEFederico Fernández Moreno
 
Adding identity management and access control to your app
Adding identity management and access control to your appAdding identity management and access control to your app
Adding identity management and access control to your appÁlvaro Alonso González
 
Teacher regional recruitment report
Teacher regional recruitment reportTeacher regional recruitment report
Teacher regional recruitment reportTom Foster
 
Keyrock - Lesson 3. Applications. How to create OAuth2 tokens.
Keyrock - Lesson 3. Applications. How to create OAuth2 tokens.Keyrock - Lesson 3. Applications. How to create OAuth2 tokens.
Keyrock - Lesson 3. Applications. How to create OAuth2 tokens.Álvaro Alonso González
 

Viewers also liked (12)

How to develop_smart_forms_01
How to develop_smart_forms_01How to develop_smart_forms_01
How to develop_smart_forms_01
 
Je lance ma startup à l'international avec les nouvelles aides de l'AWEX
Je lance ma startup à l'international avec les nouvelles aides de l'AWEXJe lance ma startup à l'international avec les nouvelles aides de l'AWEX
Je lance ma startup à l'international avec les nouvelles aides de l'AWEX
 
Café Numérique Charleroi - Les Femmes dans le Digital 26102016
Café Numérique Charleroi - Les Femmes dans le Digital 26102016 Café Numérique Charleroi - Les Femmes dans le Digital 26102016
Café Numérique Charleroi - Les Femmes dans le Digital 26102016
 
教学演示技能
教学演示技能教学演示技能
教学演示技能
 
Smartcities 2015 - ERDF
Smartcities 2015 - ERDFSmartcities 2015 - ERDF
Smartcities 2015 - ERDF
 
Online SAP BO 4.2 Training
Online SAP BO 4.2 TrainingOnline SAP BO 4.2 Training
Online SAP BO 4.2 Training
 
Go Global! Philippe Rangoni Startups.be
Go Global! Philippe Rangoni Startups.beGo Global! Philippe Rangoni Startups.be
Go Global! Philippe Rangoni Startups.be
 
How to Install and Configure your own Identity Manager GE
How to Install and Configure your own Identity Manager GEHow to Install and Configure your own Identity Manager GE
How to Install and Configure your own Identity Manager GE
 
Adding identity management and access control to your app
Adding identity management and access control to your appAdding identity management and access control to your app
Adding identity management and access control to your app
 
Smartcities 2015 - Digital aquitaine
Smartcities 2015 - Digital aquitaineSmartcities 2015 - Digital aquitaine
Smartcities 2015 - Digital aquitaine
 
Teacher regional recruitment report
Teacher regional recruitment reportTeacher regional recruitment report
Teacher regional recruitment report
 
Keyrock - Lesson 3. Applications. How to create OAuth2 tokens.
Keyrock - Lesson 3. Applications. How to create OAuth2 tokens.Keyrock - Lesson 3. Applications. How to create OAuth2 tokens.
Keyrock - Lesson 3. Applications. How to create OAuth2 tokens.
 

Similar to Catalent (CTLT) Equity Report

Dendreon Strategic Analysis
Dendreon Strategic AnalysisDendreon Strategic Analysis
Dendreon Strategic Analysisafa4
 
Healthcare Outlook 2015 Global & APAC
Healthcare Outlook 2015 Global & APACHealthcare Outlook 2015 Global & APAC
Healthcare Outlook 2015 Global & APACJay Chandran K
 
The 10 companies booming in healthcare sector small
The 10 companies booming in healthcare sector  smallThe 10 companies booming in healthcare sector  small
The 10 companies booming in healthcare sector smallinsightscare
 
The 10 Companies Booming in Healthcare Sector
The 10 Companies Booming in Healthcare SectorThe 10 Companies Booming in Healthcare Sector
The 10 Companies Booming in Healthcare Sectorinsightscare
 
Hbio slide deck sidotti 5.6.9.2014 revised 5.2.2014
Hbio slide deck sidotti 5.6.9.2014 revised 5.2.2014Hbio slide deck sidotti 5.6.9.2014 revised 5.2.2014
Hbio slide deck sidotti 5.6.9.2014 revised 5.2.2014az_hbio
 
Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021RedChip Companies, Inc.
 
The value of early asset development and commercialization
The value of early asset development and commercializationThe value of early asset development and commercialization
The value of early asset development and commercializationCello Health
 
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...Business Turku
 
2012 EY Biotech Report
2012 EY Biotech Report2012 EY Biotech Report
2012 EY Biotech ReportGautam Jaggi
 
Biotech Bulletin - Summer 2015
Biotech Bulletin - Summer 2015Biotech Bulletin - Summer 2015
Biotech Bulletin - Summer 2015Regina M Maxwell
 
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
 
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiTTC, llc
 
10 most reliable cro’s to watch in 2021
10 most reliable cro’s to watch in 202110 most reliable cro’s to watch in 2021
10 most reliable cro’s to watch in 2021insightscare
 
Biotechnology 1
Biotechnology 1Biotechnology 1
Biotechnology 1sokraturk
 
Early asset development and commercialization: Partnering for success
Early asset development and commercialization: Partnering for successEarly asset development and commercialization: Partnering for success
Early asset development and commercialization: Partnering for successCello Health
 

Similar to Catalent (CTLT) Equity Report (20)

Dendreon Strategic Analysis
Dendreon Strategic AnalysisDendreon Strategic Analysis
Dendreon Strategic Analysis
 
Healthcare Outlook 2015 Global & APAC
Healthcare Outlook 2015 Global & APACHealthcare Outlook 2015 Global & APAC
Healthcare Outlook 2015 Global & APAC
 
The 10 companies booming in healthcare sector small
The 10 companies booming in healthcare sector  smallThe 10 companies booming in healthcare sector  small
The 10 companies booming in healthcare sector small
 
The 10 Companies Booming in Healthcare Sector
The 10 Companies Booming in Healthcare SectorThe 10 Companies Booming in Healthcare Sector
The 10 Companies Booming in Healthcare Sector
 
Mera medicare
Mera medicareMera medicare
Mera medicare
 
Hbio slide deck sidotti 5.6.9.2014 revised 5.2.2014
Hbio slide deck sidotti 5.6.9.2014 revised 5.2.2014Hbio slide deck sidotti 5.6.9.2014 revised 5.2.2014
Hbio slide deck sidotti 5.6.9.2014 revised 5.2.2014
 
Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021Genetic Technologies Investor Presentation March 2021
Genetic Technologies Investor Presentation March 2021
 
The value of early asset development and commercialization
The value of early asset development and commercializationThe value of early asset development and commercialization
The value of early asset development and commercialization
 
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
 
11479_Convergence_web
11479_Convergence_web11479_Convergence_web
11479_Convergence_web
 
2012 EY Biotech Report
2012 EY Biotech Report2012 EY Biotech Report
2012 EY Biotech Report
 
Biotech Bulletin - Summer 2015
Biotech Bulletin - Summer 2015Biotech Bulletin - Summer 2015
Biotech Bulletin - Summer 2015
 
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
 
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani ZakiFuture Challenges of Clinical Development; a View from the CRO - Hani Zaki
Future Challenges of Clinical Development; a View from the CRO - Hani Zaki
 
10 most reliable cro’s to watch in 2021
10 most reliable cro’s to watch in 202110 most reliable cro’s to watch in 2021
10 most reliable cro’s to watch in 2021
 
Biotechnology 1
Biotechnology 1Biotechnology 1
Biotechnology 1
 
2008AR
2008AR2008AR
2008AR
 
2008AR
2008AR2008AR
2008AR
 
2008AR
2008AR2008AR
2008AR
 
Early asset development and commercialization: Partnering for success
Early asset development and commercialization: Partnering for successEarly asset development and commercialization: Partnering for success
Early asset development and commercialization: Partnering for success
 

Catalent (CTLT) Equity Report

  • 1. 1 Thesis & Recommendation Summary Key Investment Driver #2 Key Investment Driver #3 Catalent is the global leader in the Drug Development and manufacturing industry. Their client position allows the company to gain significantly from the sector growth Unparalleled Business Strategy leading to increased demand and contracts from leading life sciences companies, resulting in long-term stable and growing revenues As the global industry leader, Catalent maintains this status through innovation. They have developed proprietary solutions and hold around 1,300 patents, allowing them to gain in their industry through size and revenue DATE: MM/DD/YY NYSE: CTLT Sector: Life Sciences Industry: Drug Development & Manu. Associate: Leon Stempert BU Finance & Investment Club The industry is growing substantially and Catalent is positioned to make gains from this growth and continue to lead in its industry. Headwind: Pricing pressure on Life Sciences companies could slow the expected growth of the industry Key Statistics Market Cap $ 3,627.36 52-Week Range $ 18.92 – 34.40 Enterprise Value $ 5,348.8 Revenue (LTM) $ 669.3 EBITDA $ 450.8 Beta (against RTY) 0.72 Margins & Ratios P/E (LTM) 1.14x D/E Ratio 0.52 ROE 155.74% EBITDA Margin 22.88% Profit Margin 11.60% Dividend Yield 0.00% Recommendation Current Trading Price: $29.13 (As of x/xx/20xx) Recommendation: BUY Target Price: $35.99 Upside/Downside (%) 23.6% -20.00% -10.00% 0.00% 10.00% 20.00% 30.00% 40.00% 50.00% 60.00% 8/18/14 2/18/15 8/18/15 2/18/16 CTLT vs. RUT vs. PSCH CTLT Russell 2000 ETF (PSCH) Key Investment Driver #1
  • 2. 2 INDUSTRY TRENDS & PRIMARY RESEARCH INDUSTRY OVERVIEW DATE: MM/DD/YY Development and Manufacturing: Biosimilar Drug, Etc. This industry group consists of companies that either discovers, develop, or manufacture chemically based therapeutic and preventive medicine, and medicinal products. Companies included in this industry tend to collaborate with other pharmaceutical companies Industry Definition BU Finance & Investment Club Overview: Growth in Life Sciences companies are driven by a healthy economy, growing GDP and Global Healthcare Spending. Factors: Aging Population, Rising Consumer Wealth (Emerging Countries), Proliferation in chronic diseases (Longer life expectancies, etc.) Growth: Most sub-industries are expected to grow by 6-10% each year through 2020, and Increased Acquisitions in the entire sector Industry Characteristics: High R&D Costs, high capital intense, High Entry Barrier, Medium Competition (On Focused Researches) Industry Summary Growth by Segment: Pharma Segment sales have slowed in certain global markets, but are expected to maintain 6-8% to 2020 Biotech sales are expected CAGR of 9.02% through 2020 Generics and biosimilars Segment is expected to grow at a CAGR of 10.03% through 2017 All other Life Sciences sub-industries are expected to grow within 6-10% Growth Drivers: Increased trend towards Universal healthcare policies (Global Trend), Aging Population Impact on Company: Catalent end consumers are top pharmaceutical, Biotech, Generics, biosimilars, and Medtech companies. Which each segment in high growth stage, Catalent stands to gain and grow in the long-term Trend #1: Optimistic Sector Growth 1831 1587 1398 2408 402 Revenue of Peer Group ($mm) Catalent ICON Charles River PAREXEL AMRI $0.00 $1,000.00 $2,000.00 $3,000.00 $4,000.00 2016 2017 2018 2019 2020 Expected High Growth Revenues
  • 3. 3 INDUSTRY TRENDS & PRIMARY RESEARCH DATE: MM/DD/YYBU Finance & Investment Club Outlook: M&A has been increasing in this sector over the years. Deal value in 2014 was $351 billion, a 113 percent growth rate from 2013. The first half of 2015 saw 304 pharma deals valued at $221 billion, compared $62 billion same period 2014. Key Drivers: Pricing Pressure; strengthening existing product portfolios; replenishing pipelines depleted by patent expiry; deepening capabilities in priority areas, entering and/or emerging markets, and acquiring innovative technologies to leverage current assets or generate cost-saving synergies Impact on Company: Catalent has a unique business model that focuses on development, delivery, and supply. This makes the company look like a promising acquisition target. This activity also indirectly affects the company positively through stronger customers that are growing. Trend #3 Changing Demographics & Policy Changing Factors: Aging Population, Growing Prevalence of Chronic Diseases, Rising consumer wealth, and Universal healthcare programs Outcome: These factors are expected to boost healthcare spending and demand for life sciences products in 2016+ Impact on Company: Catalent supplies drug products to pharma's and ultimately the consumers. This changing environment will positively affect the sales of its services through increased healthcare spending/demand. Trend #2: M&A and Collaborations 0 200 400 600 800 1000 1200 (inthousands) Aging Population (Census Report) 0 10000 20000 30000 40000 50000 60000 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 (Inthousands) Noncommunicable Diseases (NCD)
  • 4. 4 COMPANY OVERVIEW DATE: MM/DD/YYBU Finance & Investment Club Catalent offers a range of life sciences services. From drug and biologic development services to delivery technologies to supply solutions. With over 80 years of experience, Catalent has the deepest expertise, the broadest offerings, and the most innovative technologies to help Life Sciences companies get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing results. Business Overview Drug Development & Formulation Services: With our broad range of expert services, we drive faster, more efficient development timelines and produce better products (Biologics Cell Line, Formulation, Solid State Services, Etc.) Drug Delivery Technologies: Offers better treatments and more value for patients, payers, and innovators with our innovative delivery technologies and dose forms. (Versatile SOFTGEL Solutions, Controlled Release, Inhalation, Injectable, and Oral Fast Dissolve) Supply Services: Offers global, reliable supply from our world-class manufacturing and supply network and integrated solutions Core Products & Services ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe to accelerate their research and drug development efforts PAREXEL International Corp. is a biopharmaceutical services company. It provides clinical research, medical communications, consulting, commercialization and informatics, and technology services to pharmaceutical, biotechnology, and medical device industries Albany Molecular Research, Inc. engages in research and manufacturing organization providing customers drug discovery, development, and manufacturing services. Competitors & Competitive Positioning 274.00 314.00 354.00 388.00 413.00 432.00 443.00 2009 2010 2011 2012 2013 2014 2015 Adjusted EBITDA
  • 5. 5 COMPANY OVERVIEW DATE: MM/DD/YYBU Finance & Investment Club Catalent generates its revenues through three main segments. Development and Clinical Solutions, Medication Deliveries Solutions, and Oral Technologies. Revenue Generation Finished Product/Service Back to Company Drug Manufacturing Supplies Pharmaceutical Raw Material Supplies Performed by Industry Firms Outsourced $$$ Drug Development & Formulation Services Drug Delivery Technologies Supply & Supply Management Services Biotech Companies Pharmaceutical & Biopharmaceutical companies Generics & Biosimilar Companies $0.00 $250.00 $500.00 $750.00 $1,000.00 $1,250.00 2012 2013 2014 2015 Historical Segment Revenue Development and Clinical Solutions Medication Deliveries Solutions Oral Technologies & Others $0.00 $400.00 $800.00 $1,200.00 $1,600.00 $2,000.00 $2,400.00 $2,800.00 2011 2012 2013 2014 2015 Total Revenue
  • 6. 6 MANAGEMENT OVERVIEW DATE: MM/DD/YYBU Finance & Investment Club Management Profiles John Chiminski -- Holdings: 363,000 shares – No recent activity Matthew Walsh – Holdings 88,000 shares – No recent activity Management Ownership & Insider Trading John Chiminski, CEO • More than 30+ Years of Experience in the Industry • Hired as CEO of Catalent in 2009 • Former CEO of GE Medical Diagnostics from 2007-2009, but with GE for over 20 years • Masters Degree from Kellogg School of Management; BS and MS in Electrical Engineering at Purdue University Matthew Walsh, CFO • Over 8+ Years of Life Sciences Sector experience • Hired as CFO of Catalent in 2008 • Former CFO of Escala Group, Inc. (Global Collectibles Network and Precious Metals Trader) • MBA from Cornell University; BS in Chemical Engineering at Cornell University Steve Leonard, SVP - Global Operations • More than 30+ Years of Experience in the Industry • Promoted to SVP – Global Operations of Catalent in June of 2009 • Former GM of Global Operations at GE Healthcare’s Medical Diagnostics Business • BS in Mechanical Engineering at Drexel University Holding Summary Institutional Holdings 77.5% Total number of holders 260 Total shares held 97,605,000 Total value of holdings $2,388,394,350
  • 7. 7 MANAGEMENT OVERVIEW DATE: MM/DD/YYBU Finance & Investment Club Exhibit X: Insider Trades Summary COMPANY TRENDS: INVESTMENT THESES Thesis: Catalent’s client position exposes it to the future significant growth expected in the life sciences sector. As more companies look to cut cost due to pricing pressure by government and R&D, this will drive growth of Catalent’s financials Aggressive investments to expand their sales and marketing activities has led them to grow their client accounts. Client Breakdown: • 82 of top 100 Branded drug marketers • 19 of top 20 generic marketers • 40 of top 50 biologics marketers • 23 of top 25 consumer health marketers globally • Key Customers: Pfizer, J&J, GlaxoSmithKline, Novartis, Roche, Actavis, and Teva Investment Thesis #1: Global Leader in Drug Development 0 5 10 15 20 3 Months 6 Months Number of Shares Bought Number of Shares Sold -0.02% 0.00% 0.02% 0.04% 0.06% 0.08% 0.10% 0.12% John (CEO) Matthew (CFO) Khichi Samrat Morel Donald E. JR Insider Share Change % Change 233.2 268.3 404.8 412.2 438.8 2011 2012 2013 2014 2015 Drug Development Revenues
  • 8. 8 DATE: MM/DD/YYBU Finance & Investment Club Investment Thesis #2: Unparalleled Business Model Investment Thesis #3: Patented Proprietary Solutions Thesis: Catalent business strategy has gained significant demand leading to increased contracts and contract revenue. Catalent has an unrivalled and unique Business Strategy by providing advanced delivery technologies and development solutions, as well as, supply solutions. These three major solutions allow Catalent to capitalize on demand from businesses looking to market their products faster and grow their business, while reducing the cost. Thesis: Catalent continues to innovate and develop proprietary solutions to sustain a competitive advantage in the industry. Currently, they have over 1,300 patents in advanced drug delivery and biologics formulations and technologies, manufacturing, nutritional and pharmaceutical dosage forms, mammalian cell engineering, sterile manufacturing services, and others. Notable Patents: Vegicaps and Optishell capsules, and GPEx Technology COMPANY TRENDS: INVESTMENT THESES 175.3 268.3 404.8 412.2 438.8 2011 2012 2013 2014 2015 Contract Generated Revenue 19.00% 20.00% 21.00% 22.00% 23.00% 24.00% 25.00% 2011 2012 2013 2014 2015 0.0 100.0 200.0 300.0 400.0 500.0 EBITDA & EBITDA Margins
  • 9. 9 GROWTH OPPORTUNITIES & PROJECTIONS DATE: MM/DD/YYBU Finance & Investment Club Revenue Summary & Forecast Growth as per a proxy for revenue Revenue is expected to grow with the sector through increased healthcare spending, pricing pressure, and demand from Pharmaceutical, Biotech, Biosimilar, Generics, Consumers, etc. 175 268 405 412 439 467 499 533 570 610 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Drug Development Revenue 224 219 246 262 279 297 317 339 363 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Medication Deliveries Revenue 1,203 1,176 1,169 1,130 1,107 1,096 1,096 1,107 1,118 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Oral Technologies Revenue 1,532 1,695 1,800 1,828 1,831 1,853 1,892 1,947 2,017 2,092 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Total Revenues
  • 10. 10 VALUATION: DISCOUNTED CASH FLOW ANALYSIS DATE: MM/DD/YYBU Finance & Investment Club Catalent is a leader in its industry. The industry is expected to grow by ~ 6-10% and Catalent is in the position to see revenues grow as a result. Assumptions WACC Calculation Risk-Free Rate 1.83% Equity Risk Premium 6.70% Size Premium 0.94% Beta 0.72 Cost of Equity 7.62% Cost of Debt 2.27% WACC 5.62% Historical Forecasted 2012 2013 2014 2015 2016 2017 2018 2019 2020 Revenue Growth 10.6% 6.2% 1.5% 0.2% 1.2% 2.1% 2.9% 3.6% 3.7% COGS (% of Revenue) 59.42% 59.39% 59.96% 59.43% 58.70% 58.70% 58.70% 58.70% 58.70% 58.70% EBITDA Growth 2.07% 11.76% 6.97% 2.98% -1.33% 2.08% 2.89% 3.62% 3.71% EBITDA (% of Revenue) 21.8% 20.10% 21.10% 22.30% 22.90% 22.3% 22.3% 22.3% 22.3% 22.3% EBIT Growth -1.54% 8.31% 15.70% 5.38% -7.06% 0.86% 1.64% 2.35% 2.42% EBIT (% of Revenue) 14.0% 12.40% 12.70% 14.40% 15.20% 13.90% 13.80% 13.60% 13.40% 13.30% NWC 372.2 126.4 162.4 160.1 187.2 204.1 208.4 214.4 222.2 230.4 FCFF Calculation Forecasted 2016 2017 2018 2019 2020 EBIT $258.38 $260.60 $264.87 $271.09 $277.64 - Taxes $90.43 $91.21 $92.70 $94.88 $97.17 $348.81 $351.81 $357.57 $365.97 $374.81 + D&A $154.85 $161.24 $169.15 $178.64 $188.76 - CAPEX $196.39 $199.48 $216.46 $235.47 $249.30 - Δ in NWC $16.94 $4.25 $6.01 $7.76 $8.23 Unlevered FCF $290.33 $309.32 $304.24 $301.38 $306.03 Net Present Value $1,285.34
  • 11. 11 VALUATION: DISCOUNTED CASH FLOW ANALYSIS DATE: MM/DD/YYBU Finance & Investment Club Terminal Value Calculation Catalent is about to release its latest fiscal year data in the coming weeks. The data used to calculate the intrinsic value is a bit stale, however, using the relative value multiple, a more accurate implied price becomes apparent. Key Takeaways DCF Valuation Growth Rate 2.00% Undiscounted TEV $ 8,620 Discounted TEV $ 6,558 Implied Exit Multiple 10.20x Enterprise Value $ 7,843 Equity Value $ 6,122 Implied Share Price $ 49.17 WACC/Growth Rate Price Sensitivity WACC $49.17 4% 4.6% 5.1% 5.6% 6.1% 6.6% 7.1% 7.6% GrowthRate 3.0% $181.03 $121.09 $ 89.47 $ 69.97 $ 56.76 $ 47.23 $ 40.05 $ 34.44 2.5% $123.49 $ 91.26 $ 71.37 $ 57.90 $ 48.19 $ 40.86 $ 35.15 $ 30.57 2.0% $ 93.08 $ 72.80 $ 59.07 $ 49.17 $ 41.70 $ 35.87 $ 31.20 $ 27.39 1.50% $ 74.27 $ 60.27 $ 50.17 $ 42.55 $ 36.61 $ 31.85 $ 27.96 $ 24.73 1.00% $ 61.49 $ 51.19 $ 43.42 $ 37.36 $ 32.51 $ 28.55 $ 25.25 $ 22.47 0.50% $ 52.24 $ 44.32 $ 38.14 $ 33.19 $ 29.15 $ 25.78 $ 22.95 $ 20.52 3.5% $283.42 $178.90 $127.52 $96.96 $76.70 $62.29 $51.51 Valuation Output: 1yr Price Target $ 35.99 Current Price $ 29.13 Upside Potential 23.6% Recommendation BUY
  • 12. 12 VALUATION: COMPARABLE COMPANIES ANALYSIS DATE: MM/DD/YYBU Finance & Investment Club - Comps Comparable, but not identical. Some comps have different segments - More accurate representation of the implied share price than intrinsic approach Key Takeaways Name TKR ICON ICLR Charles River Labs CRL PAREXEL PRXL Albany Molecular Research AMRI Wide Comparable Companies Wide CompCo Results EV/Sales EV/EBITDA Target 8.0x 11.9x Max 8.0x 11.9x Mean 6.1x 10.2x Median 5.7x 10.0x Min 4.6x 9.1x
  • 13. 13 DATE: MM/DD/YYBU Finance & Investment Club VALUATION SUMMARY & RANGE ANALYSIS Catalent looks to be positioned to take advantage of growth in the industry. My price target seems fairly reasonable. Consider investing into a company and industry the fund doesn’t have much exposure to. Key Takeaways Methodology Price / Share Weight Discounted Cash Flow Perpetuity Growth $16.53 50% Exit Multiple $25.56 25% Comparable Company EV/Sales - Core $16.73 5% EV/EBITDA $22.35 10% P/E $19.49 10% Target Price/Share $35.99 Valuation Summary >>Income Approach (75%) • The overall growth expected for the industry is driving the intrinsic valuation assumptions >>Market Approach (25%) • EV/EBITDA more of an appropriate metic for this industry • Comps are good comparables, but have other segments Assumptions: change weights to fit your analysis Valuation Football Field
  • 16. 16 Appendix 3: Cash Flow Statement

Editor's Notes

  1. McNew & Saania
  2. Make headlines a cause-effect thesis – e.g. “Economies of Scale Driving Industry Consolidation” Common trends: Changes in underlying commodity prices because of some supply/demand change Industry consolidation increasing prices or driving out high-cost competition Substitute goods driving down demand Changes in consumer preferences Cyclical effects – indicate leverage (consider regression) and whether positive or negative correlation Foreign companies entering market or exporting at lower cost Changes in supply chain structure, e.g. outsourcing part of the business overseas Regulatory/legal changes Expansion/contraction of capacity Technological changes Changes in underlying demographics Geographic expansion Increasing/decreasing multiple valuations
  3. Make headlines a cause-effect thesis – e.g. “Economies of Scale Driving Industry Consolidation” Common trends: Changes in underlying commodity prices because of some supply/demand change Industry consolidation increasing prices or driving out high-cost competition Substitute goods driving down demand Changes in consumer preferences Cyclical effects – indicate leverage (consider regression) and whether positive or negative correlation Foreign companies entering market or exporting at lower cost Changes in supply chain structure, e.g. outsourcing part of the business overseas Regulatory/legal changes Expansion/contraction of capacity Technological changes Changes in underlying demographics Geographic expansion Increasing/decreasing multiple valuations Aging Population Source: https://www.census.gov/content/dam/Census/library/publications/2016/demo/p95-16-1.pdf
  4. Management Profiles: Benchmark performance against peer group since took over Note any significant market cap growth of companies where previously in leadership Note any improvement in margins, etc. above industry Note any preference for organic growth vs. acquisitions Note any preference for debt load Note capital expenditure habits Note dividends/share buybacks Note if manager has outperformed in both good and bad cycles for the industry Note if there have been any accounting scandals or significant earnings revisions Note compensation in stock/stock options
  5. Note insider buying/selling as well as flat ownership %’s – high ownership and insider buying highly correlated with performance, especially in the small-cap space Note: asymmetric in that there are plenty of non-damning reasons to sell but only one reason to buy Common theses: Underappreciated changes in fundamentals Likely acquisition target Cheap on a relative basis without good reason Depressed stock price for some reason we do not view as important Unrecognized valuable asset – real estate, brand name, etc. Particularly good exposure to a positive trend Minimal downside due to very low valuation with no BK risk Pricing does not reflect market commodity pricing Market commodity pricing does not reflect our expectations Unlocked value through financial engineering Strong, steady cash flows with high dividend yield Massive market size allows company to grow for decades Superior operating model reduces costs, increases flexibility, etc. Contractual agreements lock in certain cash flows – low risk New product poised to deliver market share gains Geographic expansion offer considerable upside Soon-to-be-realized estimates of pent-up demand Historical lows of time-series multiple valuation, should return to average Etc.
  6. Common theses: Underappreciated changes in fundamentals Likely acquisition target Cheap on a relative basis without good reason Depressed stock price for some reason we do not view as important Unrecognized valuable asset – real estate, brand name, etc. Particularly good exposure to a positive trend Minimal downside due to very low valuation with no BK risk Pricing does not reflect market commodity pricing Market commodity pricing does not reflect our expectations Unlocked value through financial engineering Strong, steady cash flows with high dividend yield Massive market size allows company to grow for decades Superior operating model reduces costs, increases flexibility, etc. Contractual agreements lock in certain cash flows – low risk New product poised to deliver market share gains Geographic expansion offer considerable upside Soon-to-be-realized estimates of pent-up demand Historical lows of time-series multiple valuation, should return to average Etc. GPEx: Used to develop stable, high-yielding mammalian cell lines for both innovator and bio-similar biologic compounds
  7. Include choice of comps, why, and what benchmark you used (e.g. median, median and mean, regression) Weighting of comps with resulting target prices